The stock of ChemoCentryx Inc (NASDAQ:CCXI) is a huge mover today! The stock increased 9.03% or $0.5 on September 30, hitting $6.04. About 239,528 shares traded hands or 9.51% up from the average. ChemoCentryx Inc (NASDAQ:CCXI) has risen 67.88% since February 26, 2016 and is uptrending. It has outperformed by 57.45% the S&P500.
The move comes after 7 months positive chart setup for the $283.37 million company. It was reported on Sep, 30 by Barchart.com. We have $12.02 PT which if reached, will make NASDAQ:CCXI worth $280.54 million more.
Analysts await ChemoCentryx Inc (NASDAQ:CCXI) to report earnings on November, 14.
According to Zacks Investment Research, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.”
Insitutional Activity: The institutional sentiment decreased to 1.11 in 2016 Q2. Its down 0.65, from 1.76 in 2016Q1. The ratio is negative, as 12 funds sold all ChemoCentryx Inc shares owned while 23 reduced positions. 20 funds bought stakes while 19 increased positions. They now own 22.71 million shares or 5.49% less from 24.03 million shares in 2016Q1.
Geduld E E, a New York-based fund reported 25,000 shares. Fernwood Limited Liability Co has 0.04% invested in the company for 10,000 shares. Parametric Portfolio Ltd Com, a Washington-based fund reported 34,422 shares. The New York-based Millennium Mngmt Limited Com has invested 0% in ChemoCentryx Inc (NASDAQ:CCXI). Highbridge Capital Lc, a New York-based fund reported 39,966 shares. The California-based Blackrock Fund Advsr has invested 0% in ChemoCentryx Inc (NASDAQ:CCXI). Proshare Ltd Liability Com has 0% invested in the company for 38,159 shares. Oxford Asset accumulated 0.1% or 536,521 shares. Baker Bros Advisors Lp has 0% invested in the company for 49,064 shares. Nationwide Fund Advsrs, a Pennsylvania-based fund reported 96,077 shares. Acadian Asset Mngmt Limited Liability Company has 0% invested in the company for 4,771 shares. Geode Capital Mngmt Lc reported 147,922 shares or 0% of all its holdings. D E Shaw And Company last reported 0% of its portfolio in the stock. Franklin Res Incorporated holds 0.01% or 2.17 million shares in its portfolio. Blackrock Ltd Com accumulated 205,673 shares or 0% of the stock.
Insider Transactions: Since May 13, 2016, the stock had 3 insider buys, and 2 insider sales for $420,502 net activity. On Tuesday, May 17 Edwards Thomas A. bought $202,500 worth of the stock or 50,000 shares. $24,337 worth of ChemoCentryx Inc (NASDAQ:CCXI) was sold by Tyree James L on Saturday, May 21. 4,000 shares were sold by LUCAS ROGER C, worth $20,262 on Thursday, September 1. Parker Geoffrey M. also bought $161,388 worth of ChemoCentryx Inc (NASDAQ:CCXI) shares.
Another recent and important ChemoCentryx Inc (NASDAQ:CCXI) news was published by Quotes.Wsj.com which published an article titled: “ChemoCentryx Inc. CCXI (US: Nasdaq)” on February 04, 2012.
CCXI Company Profile
ChemoCentryx, Inc. (ChemoCentryx), incorporated on November 8, 1996, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.